Rosiglitazone Appears to Reduce In-Stent Restenosis
The peroxisomal proliferator–activated receptor-gamma agonist rosiglitazone appears to reduce the risk of in-stent restenosis in atherosclerotic coronary arteries, a new study shows. […]
You may also like
Toll-like Receptor 9 and the Inflammatory Response to Surgical Trauma and Cardiopulmonary Bypass
CPB, surgical trauma and ischemic perfusion injury trigger the release of circulating mtDNA that activates TLR-9, in turn stimulating a release of IL-6. Therefore, TLR-9 antagonists may attenuate this response and may provide a future therapeutic target whereby the systemic inflammatory response to cardiac surgery may be manipulated to improve clinical outcomes.
1 min read
Venous or Arterial Samples for Activated Clotting Time Measurements: A Systematic Review
Sampling source should be kept consistent to facilitate effective haemostatic strategies. More research is needed regarding variability in vascular surgery and novel clot assessment techniques.
1 min read